<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01842256</url>
  </required_header>
  <id_info>
    <org_study_id>142HPS13002</org_study_id>
    <nct_id>NCT01842256</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.</brief_title>
  <acronym>CKD-345</acronym>
  <official_title>A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin After Oral Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the&#xD;
      pharmacokinetic properties of atorvastatin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      healthy subjects are administrated single-dose over the period Ⅰand Ⅱ(Crossover) of&#xD;
      telmisartan/s-amlodipine, atorvastatin and atorvastatin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In the steady state atorvastatin 40mg AUClast</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>AUClast: Area under the plasma concentration time curve from zero time until the last measurable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>In the steady state atorvastatin 40mg Cmax</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>Cmax: maximum plasma drug concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In the steady state atorvastatin 40mg AUCinf</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>AUCinf: Area Under the Concentration time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state atorvastatin 40mg Tmax</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>Tmax: Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state atorvastatin 40mg t1/2</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>t1/2: Observed terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>From 1day to 17days</time_frame>
    <description>Evaluated safety parameters included: physical examination, vital sign, laboratory test, ECG&#xD;
Adverse event monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Orthohydroxy-atorvastatin AUClast</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>AUClast: Area under the plasma concentration time curve from zero time until the last measurable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Orthohydroxy-atorvastatin Cmax</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>Cmax: maximum plasma drug concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Orthohydroxy-atorvastatin AUCinf</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>AUCinf: Area Under the Concentration time curve from time zero to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Orthohydroxy-atorvastatin Tmax</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>Tmax: Time to Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In the steady state Orthohydroxy-atorvastatin t1/2</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48hr post-dose</time_frame>
    <description>t1/2: Observed terminal elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg</intervention_name>
    <description>3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),&#xD;
oral intake, once in a period&#xD;
over the period Ⅰ&amp;Ⅱ(crossover)</description>
    <arm_group_label>Atorvastatin 40mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 40mg</intervention_name>
    <description>1 Tablet (atorvastatin 40mg),&#xD;
oral intake, once in a period&#xD;
over the period Ⅰ&amp;Ⅱ(crossover)</description>
    <arm_group_label>Atorvastatin 40mg</arm_group_label>
    <arm_group_label>Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 20 aged and 45 aged in healthy male and female&#xD;
&#xD;
          2. Body weight more than 55kg in male, 50kg in female&#xD;
&#xD;
          3. Body Mass Index more than 18.5 and under 25 (Body Mass Index(kg/m2)= kg/(m)2)&#xD;
&#xD;
          4. If female, must include more than one among the items&#xD;
&#xD;
               1. The menopause (there is no natural menses for at least 2 years)&#xD;
&#xD;
               2. Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or&#xD;
                  other methods of infertility condition)&#xD;
&#xD;
               3. The male partner infertility before screening (Demonstrated azoospermia after&#xD;
                  vasectomy)and if this man is the only partner of the female subject.&#xD;
&#xD;
               4. you are using one of the following contraceptive measure for 3 months before&#xD;
                  screening, and Necessarily you agree that used continuously contraceptive measure&#xD;
                  during the clinical trial and for 1 month after the final dosing investigational&#xD;
                  product.(But, should not use a device of contraception or oral contraceptive drug&#xD;
                  that containing a hormonal caused telmisartan, s-amlodipine, atorvastatin calcium&#xD;
                  drug interactions during the clinical trials)&#xD;
&#xD;
                    -  Abstinence.&#xD;
&#xD;
                    -  Physical interrupt method (such as a condom, contraceptive diaphoretic or&#xD;
                       cervical cap)&#xD;
&#xD;
               5. In case of women of childbearing age, the serum β-hCG pregnancy test is negative,&#xD;
                  and urine β-hCG test is negative before taking the investigational product.&#xD;
&#xD;
          5. If men has sexual life with women of childbearing age, Necessarily he agrees that use&#xD;
             condoms during clinical trials and do not sperm donation during clinical trials and&#xD;
             until one month after the final dosage of investigational products&#xD;
&#xD;
          6. Those who fully understand about this clinical trial after enough hearing, and then&#xD;
             decided to join the clinical trials by themselves and to comply with the precautions&#xD;
             written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have clinically significant disease that hepatobiliary system(severe hepatic&#xD;
             impairment, etc), kidney(severe renal impairment, etc.), nervous system, immune&#xD;
             system, respiratory system, endocrine system,hemato-oncology disease, cardiovascular&#xD;
             system (heart failure, etc.).or mental illness, or a history of mental disease.&#xD;
&#xD;
          2. Have a gastrointestinal disease history that can affect drug absorption (Crohn,&#xD;
             ulcers, etc.) or surgery (except simple appendectomy or hernia surgery)&#xD;
&#xD;
          3. Hypersensitivity reaction to drug or clinically significant hypersensitivity reaction&#xD;
             in the history of Investigational drugs (telmisartan, s-amlodipine or atorvastatin&#xD;
             calcium) or additives&#xD;
&#xD;
          4. An impossible one who participates in clinical trial including screening tests(medical&#xD;
             history taking, BP, physical examination, 12-lead ECG, blood &amp; urine laboratory test&#xD;
             result) within 28 days before the beginning of study treatment.&#xD;
&#xD;
          5. Defined by the following laboratory parameters:&#xD;
&#xD;
               -  AST, ALT&gt; 1.25*upper limit of normal range&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5* upper limit of normal range&#xD;
&#xD;
               -  CPK &gt; 1.5* upper limit of normal range&#xD;
&#xD;
               -  eGFR(using by MDRD method) &lt; 60 mL/min/1.73m2&#xD;
&#xD;
          6. Sitting SBP &gt; 150 mmHg or &lt; 90 mmHg, Sitting DBP&gt; 100 mmHg or &lt; 50 mmHg , after&#xD;
             5minuts break.&#xD;
&#xD;
          7. Drug abuse or have a history of drug abuse showed a positive for the Triage TOX drug&#xD;
             on urine.&#xD;
&#xD;
          8. Pregnant or lactating women.&#xD;
&#xD;
          9. A heavy caffeine consumer(caffeine&gt;5cups/day), alcohol consumer(alcohol&gt;210g/week), or&#xD;
             smoker(cigarette&gt;10cigarettes /day)&#xD;
&#xD;
         10. Subject takes ethical drug or herbal medicine within 14days, OTC within 7days before&#xD;
             the beginning of study treatment but investigator determine that the taking drug&#xD;
             affect this study or could affect the safety of the subjects.&#xD;
&#xD;
         11. Subject who takes inhibitors and inducers of drug metabolizing enzyme(Barbiturates&#xD;
             etc.) within 30 days.&#xD;
&#xD;
         12. Taking foods containing grapefruit within 7 days before the beginning of study&#xD;
             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days&#xD;
             before the beginning of study treatment)&#xD;
&#xD;
         13. Subject who treated with any investigational drugs within 60days before the beginning&#xD;
             of study treatment (However, biologicals applies for 90 days, but can be based on a&#xD;
             more extended period of time by considering the half-life.&#xD;
&#xD;
         14. Previously donate whole blood within 60 days or component blood within 30days.&#xD;
&#xD;
         15. An impossible one who participants in clinical trial by investigator's decision&#xD;
             including laboratory test result or another reason.&#xD;
&#xD;
         16. Positive for Hepatitis B, Hepatitis C, HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Soo Park, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>April 25, 2013</study_first_submitted>
  <study_first_submitted_qc>April 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2013</study_first_posted>
  <last_update_submitted>July 31, 2013</last_update_submitted>
  <last_update_submitted_qc>July 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Telminouveau</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Essential Hypertension</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

